Olaparib for ovarian cancer: a single-institution, multi-site qualitative study.

Nichole A MartinMina HannaChristopher EhretGladys AsieduAminah Jatoi

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2022)

Although oral maintenance therapy for ovarian cancer is relatively new, patients appear willing to take olaparib long term; and they seem to take great lengths to remain adherent, despite having sometimes had a long cancer journey.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
papillary thyroid
prognostic factors